BEAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Beam Therapeutics Inc (BEAM) is not a strong buy for a beginner, long-term investor at this time. While there are positive catalysts such as hedge fund interest and upcoming regulatory updates, the company's financial performance is weak, insider selling is significant, and technical indicators do not suggest a strong upward trend. The lack of recent AI Stock Picker or SwingMax signals further supports a cautious approach. Holding the stock or waiting for clearer positive signals is recommended.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 45.678, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting a lack of strong directional trend. Key support is at 24.918, and resistance is at 28.707. Overall, technical indicators are neutral to slightly bearish.
Hedge funds are significantly increasing their positions, with a 161.22% rise in buying activity.
Analysts have raised price targets recently, with Bernstein increasing to $41 and BofA to $45, citing positive regulatory updates and upcoming data catalysts.
The stock has a 60% chance of gaining 24.32% in the next month based on historical patterns.
Insiders are selling heavily, with a 980.39% increase in selling activity over the last month.
Financial performance is weak, with revenue dropping 32.03% YoY and EPS declining 5.98% YoY in Q3
No recent news or significant event-driven catalysts in the past week.
In Q3 2025, revenue dropped by 32.03% YoY to $9.69M. Net income improved slightly but remains negative at -$112.73M, up 16.61% YoY. EPS fell by 5.98% YoY to -1.1. Gross margin remains strong at 100%, but overall financials indicate weak growth and profitability.
Analysts are cautiously optimistic. Bernstein raised its price target to $41 and maintains an Outperform rating, citing positive regulatory updates and upcoming data catalysts. BofA raised its target to $45 with a Buy rating, highlighting improving biotech fundamentals. However, UBS initiated coverage with a Neutral rating and a $28 price target, reflecting mixed sentiment among analysts.
